Item 2.02 Results of Operations and Financial Condition.
On February 7, 2023, Magenta Therapeutics, Inc. (the "Company" or "Magenta")
announced that as of December 31, 2022, the Company's cash, cash equivalents and
marketable securities were approximately $112 million.
The cash, cash equivalents and marketable securities information above is based
on preliminary unaudited information and management estimates for the year ended
December 31, 2022, is not a comprehensive statement of the Company's financial
results as of and for the fiscal year ended December 31, 2022 and is subject to
completion of the Company's financial closing procedures. The Company's
independent registered public accounting firm has not conducted an audit or
review of, and does not express an opinion or any other form of assurance with
respect to, this preliminary estimate.
The information contained in this item is being furnished and shall not be
deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as
expressly set forth by specific reference in such filing.
Item 2.05 Costs Associated with Exit or Disposal Activities.
On February 6, 2023, the Board of Directors (the "Board") of the Company
approved a restructuring plan (the "Plan") to reduce the Company's operations to
preserve financial resources, resulting in a reduction of the Company's
workforce by up to 56 positions, or approximately 84%, to be substantially
completed by February 17, 2023. As a result of the Plan, the Company expects to
incur estimated severance and related costs of $5.4 million by the end of
February 2023.
Each departing employee of Magenta has played an integral role in the Company's
mission of improving stem cell transplant to enable access for more patients.
Magenta would like to sincerely thank its departing employees for their hard
work and dedication, and the Company wishes them well in their future endeavors.
As the Plan is implemented, the Company's management will re-evaluate the
estimated costs and expenses set forth above and may revise the estimated
restructuring charge as appropriate, consistent with generally accepted
accounting principles. The estimated charges that the Company expects to incur
in connection with the Plan are subject to a number of assumptions, and actual
results may differ materially from these estimates. The Company may also incur
additional costs not currently contemplated due to events that may occur as a
result of, or that are associated with, the Plan.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangement of Certain
Officers.
In connection with the Plan, as discussed in Item 2.05 above, the following
members of the Company's executive team, (i) Jason Gardner, President and Chief
Executive Officer, (ii) David Nichols, Chief Technical Officer, (iii) Caren
Deardorf, Chief Commercial Officer, (iv) Kristen Stants, Chief People Officer
and (v) Shawn Rose, Senior Vice President and Head of Clinical Development, will
be leaving the Company to pursue new opportunities. The Company plans to enter
into consulting agreements with Dr. Gardner, Mr. Nichols and Ms. Deardorf on
terms yet to be determined, but are contemplated to be on an as requested basis
and at an hourly rate for work performed. Dr. Gardner will no longer serve as a
director of the Company, effective as of February 7, 2023. Dr. Gardner's
resignation from the Board was not due to any disagreement with the Company's
operations, policies or practices.
Magenta would like to thank Dr. Gardner, Mr. Nichols, Ms. Deardorf, Ms. Stants
and Dr. Rose for their commitment and guidance to the Company.
Each departing member of the Company's executive team will be entitled to
receive severance upon the execution of a separation agreement satisfactory to
Magenta. Assuming the execution of this agreement, (i) Dr. Gardner will be
entitled to receive severance benefits pursuant to the terms of his Amended and
Restated Employment Agreement with the Company, with an effective date of
March 3, 2022, attached as Exhibit 10.12 to our Annual Report on Form 10-K filed
with the SEC on March 8, 2023, and (ii) Mr. Nichols will be entitled to receive
severance benefits pursuant to the terms of his Amended and Restated Employment
Agreement with the Company, with an effective date of May 2, 2022, attached as
Exhibit 10.2 to our Current Report on Form 8-K filed with the SEC on May 2,
2022.
2
--------------------------------------------------------------------------------
In connection with the Plan, Stephen Mahoney, Chief Financial and Operating
Officer, was named President of the Company.
Cautionary Note Regarding Forward Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995, as amended.
These statements include, without limitation, implied and express statements
relating to: the Company's preliminary unaudited cash position as of December
31, 2022; the Company's approved restructuring plan, including, without
limitation, the expected size of the restructuring and severance and related
costs; and the Company's plans to retain certain individuals as consultants.
Words such as "anticipate," "believe," "continue," "could," "designed,"
"endeavor," "estimate," "expect," "intend," "may," "might," "plan," "potential,"
"predict," "project," "seek," "should," "target," "preliminary," "will," "would"
and similar expressions are intended to identify forward-looking statements. The
express or implied forward-looking statements included in this Current Report on
Form 8-K are only predictions and are subject to a number of risks,
uncertainties and assumptions, including, without limitation: the risk that the
restructuring costs and charges may be greater than anticipated or incurred in
different periods than anticipated; the risk that the Company's restructuring
efforts may adversely affect the Company's internal programs and the Company's
ability to recruit and retain skilled and motivated personnel, and may be
distracting to employees and management; the risk that the Company's
restructuring efforts may negatively impact the Company's business operations
and reputation with or ability to serve customers; and the risk that the
Company's restructuring efforts may not generate their intended benefits to the
extent or as quickly as anticipated. These and other risks are described in
additional detail in Magenta's Quarterly Report on Form 10-Q for the quarter
ended September 30, 2022, and its other filings made with the Securities and
Exchange Commission from time to time. Any forward-looking statements contained
in this Current Report on Form 8-K represent Magenta's views only as of today
and should not be relied upon as representing its views as of any subsequent
date. Magenta explicitly disclaims any obligation to update any forward-looking
statements, except to the extent required by law.
3
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses